Detalles de la búsqueda
1.
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
PLoS One;
19(5): e0302548, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38728337
2.
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
Ther Adv Urol;
16: 17562872241229876, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38425504
3.
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
Eur J Cancer;
201: 113589, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38382153
4.
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Oncologist;
29(2): 142-150, 2024 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37589219
5.
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
Eur Urol;
85(2): 154-163, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37714742
6.
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
J Clin Oncol;
42(5): 571-583, 2024 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37963304
7.
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Eur Urol Oncol;
2023 Oct 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37813745
8.
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA Oncol;
9(12): 1629-1638, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37883073
9.
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
J Manag Care Spec Pharm;
29(7): 758-768, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37404070
10.
Management of cancer treatments in hemodialysis patients.
Bull Cancer;
2023 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36931910
11.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Eur J Cancer;
182: 66-76, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36746010
12.
[A 2022 inventory in oncology news]. / Que retenir dans la prise en charge des cancers en 2022 ?
Bull Cancer;
110(1): 19-31, 2023 Jan.
Artículo
en Francés
| MEDLINE | ID: mdl-36529541
13.
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
Clin Cancer Res;
29(1): 81-91, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36043882
14.
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
BMC Cancer;
22(1): 1213, 2022 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36434554
15.
Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study.
Clin Genitourin Cancer;
20(6): 533-542, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36050262
16.
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Lancet Oncol;
23(10): 1297-1307, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36063830
17.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol;
23(9): 1133-1144, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36055304
18.
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Eur J Cancer;
175: 43-53, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36088671
19.
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Clin Genitourin Cancer;
20(5): 488-494, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35977881
20.
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Eur Urol Oncol;
5(5): 577-584, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35853818